ATLANTA, GA – – (Businesswire – October 11, 2018) – – Holzer & Holzer, LLC is investigating whether certain statements issued by Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) complied with federal securities laws. On October 9, 2018, the minutes from Trevena’s April 28, 2016 meeting with the Food and Drug Administration (“FDA”) were released, which disclosed that the FDA “did not agree” with several aspects of Trevena’s Phase 3 study for Oliceridine. The price of Trevena’s stock declined following the report. If you purchased Trevena common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.